•  
  •  
 

Abstract

Objective: This study aimed to evaluate the effects of immunoglobulin use on clinical treatment outcomes, prognosis, and laboratory parameters in neonates with septic shock. Methods: In the study, 155 newborns treated in the Neonatal Intensive Care Unit of Selcuk University Faculty of Medicine between 2019 and 2024 were retrospectively analyzed. Newborns were divided into three groups: those receiving IgM-enriched IVIG (pentaglobin®) treatment, those receiving standard IVIG treatment containing only IgG, and those receiving no immunoglobulin treatment. Laboratory parameters and clinical outcomes were compared and statistically analyzed before and after treatment. Results: Of 155 newborns, 71 (45.8%) were female and 84 (54.2%) were male. The lowest birth weight was 450 g, and the highest was 4000 g, with a mean of 1420.55 ± 822.90 g. Hematocrit (34.92 ± 9.45 %), platelet count (106.78 ± 105.67 x103/μL), blood glucose (124.58 ± 68.00 mg/dL), HCO3 (19.21 ± 6.10 mEq/L) and base deficit (-6.82 ± 8.33 mmol/L) were found in newborns receiving pentaglobin® before treatment. One week after treatment, hematocrit (32.03 ± 6.40 %), platelet count (194.88 ± 171.28 x103/μL), blood glucose (88.41 ± 45.63 mg/dL), HCO3 (23.16 ± 5.87 mEq/L) and base deficit (-1.65 ± 7.57 mmol/L) were determined. A statistically significant difference was found in hematocrit, platelet count, glucose, bicarbonate, and base deficit values before and after treatment in newborns receiving pentaglobin® (p<0.05). Conclusion: Biochemical parameters such as hematocrit, platelet count, glucose, bicarbonate, and base deficit have shown favorable improvement in the treatment prognosis in neonates with septic shock receiving pentaglobin®. However, larger patient groups and prospective studies are needed to evaluate the efficacy of different IVIG preparations in the treatment of septic shock.

Download

Share

COinS